


**Product Name** : ADS032  
**Cat. No.** : PC-20956  
**CAS No.** : 2757333-37-0  
**Molecular Formula** : C<sub>22</sub>H<sub>29</sub>NO<sub>4</sub>S  
**Molecular Weight** : 403.54  
**Target** : NOD-like Receptor (NLR)  
**Solubility** : 10 mM in DMSO



CAS: 2757333-37-0

## Biological Activity

ADS032 (ADS-032) is the first, reversible and stable dual **NLRP1** and **NLRP3** inflammasome inhibitor, inhibits nigericin-induced NLRP3-induced IL-1 $\beta$  secretion from LPS-primed iBMDMs with IC<sub>50</sub> of 30  $\mu$ M.

ADS032 inhibits ionophore- (nigericin) and crystalline- (silica) induced IL-1 $\beta$  and LDH secretion from LPS-primed iBMDMs, respectively, with no effect on LPS-induced TNF- $\alpha$  production.

ADS032 dose dependently inhibits IL-1 $\beta$  secretion induced by the NLRP1 agonist L18-MDP, but MCC950 has no effect.

ADS032 reduces L18-MDP-induced IL-1 $\beta$  secretion in both WT and NLRP3-deficient macrophages in a dose-dependent manner.

ADS032 directly interacts proximal to the Walker B motif within the NACHT domain of both NLRP1 and NLRP3, thus inhibiting inflammasome activation and formation of each inflammasome complex.

ADS032 (20-350  $\mu$ M) dose dependently reduces NLRP3-induced ASC oligomerisation.

ADS032 effectively inhibits NLRP1 and NLRP3 inflammasome activity in human macrophages and bronchial epithelial cells.

ADS032 (200 mg /kg, methylcellulose, i.p.) inhibits NLRP3 in vivo and reduces acute silicosis-associated pulmonary inflammation in vivo.

## References

Docherty CA, et al. *Clin Transl Immunology*. 2023 Jun 22;12(6):e1455.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com